Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
Valuation and Earnings
This table compares Nurix Therapeutics and HCW Biologics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $76.99 million | 9.69 | -$143.95 million | ($2.66) | -5.71 |
| HCW Biologics | $3.93 million | 10.79 | -$24.99 million | ($0.76) | -1.47 |
HCW Biologics has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 0 | 1 | 8 | 0 | 2.89 |
| HCW Biologics | 0 | 0 | 0 | 0 | N/A |
Nurix Therapeutics presently has a consensus target price of $23.33, indicating a potential upside of 53.71%. Given Nurix Therapeutics’ higher probable upside, research analysts plainly believe Nurix Therapeutics is more favorable than HCW Biologics.
Profitability
This table compares Nurix Therapeutics and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -178.93% | -67.08% | -43.62% |
| HCW Biologics | -697.53% | -146.76% | -81.74% |
Risk & Volatility
Nurix Therapeutics has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.
Institutional and Insider Ownership
3.0% of HCW Biologics shares are held by institutional investors. 7.2% of Nurix Therapeutics shares are held by insiders. Comparatively, 49.9% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Nurix Therapeutics beats HCW Biologics on 7 of the 13 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
